$465.67−0.30%Close 13 Nov 2026 · Market value $253.3B
About Amgen
Amgen Inc. discovers, develops, manufactures and delivers biologic and small molecule medicines for serious diseases, with a stated focus on areas of high unmet medical need. Its marketed products include Prolia, XGEVA, Repatha, Otezla, ENBREL, EVENITY, TEPEZZA, BLINCYTO, Nplate, TEZSPIRE, KYPROLIS, Aranesp, KRYSTEXXA and Vectibix, along with biosimilar products. Its customers include healthcare providers, dialysis centers, hospitals and pharmacies, and in the United States it sells principally to pharmaceutical wholesale distributors. The largest concentration of its sales and marketing operations is in the United States and Europe, and it markets products in approximately 100 countries. Manufacturing is performed at facilities in the United States, Ireland, the Netherlands and Singapore, and distribution centers operate in Puerto Rico, Kentucky, California and the Netherlands.
A summary of the business section of the company's latest annual report, filed 13 Feb 2026.
Company facts
| Ticker | AMGN · Nasdaq |
|---|
| Sector | Biotechnology |
|---|
| Industry | Biotechnology |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 318154 |
|---|
| Latest annual report | 10-K, filed 13 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Robert A. Bradway | Chairman, CEO and President · Director | 1.5M · < 1% | Shares withheld for tax, 7 May 2026 |
|---|
| Murdo Gordon | EVP, Global Commercial Ops | 225K · < 1% | Shares withheld for tax, 7 May 2026 |
|---|
| David M. Reese | EVP & Chief Technology Officer | 225K · < 1% | Shares withheld for tax, 7 May 2026 |
|---|
| Peter H. Griffith | EVP & CFO | 170K · < 1% | Shares withheld for tax, 7 May 2026 |
|---|
| James E. Bradner | EVP, Research and Development | 18.5K · < 1% | Shares withheld for tax, 7 May 2026 |
|---|
| Greg C. Garland | Director | 13.2K · < 1% | Grant or award, 19 May 2026 |
|---|
| Robert A. Eckert | Director | 8.0K · < 1% | Grant or award, 19 May 2026 |
|---|
| Wanda M. Austin | Director | 7.4K · < 1% | Grant or award, 19 May 2026 |
|---|
| Tyler Jacks | Director | 3.4K · < 1% | Grant or award, 19 May 2026 |
|---|
| Brian J. Druker | Director | 3.2K · < 1% | Grant or award, 19 May 2026 |
|---|
| Charles M. Holley, Jr. | Director | 1.3K · < 1% | Grant or award, 7 Aug 2026 |
|---|
| S. Omar Ishrak | Director | 935 · < 1% | Grant or award, 7 Aug 2026 |
|---|
| Mary E. Klotman | Director | 719 · < 1% | Grant or award, 19 May 2026 |
|---|
| Ellen J. Kullman | Director | 410 · < 1% | Grant or award, 19 May 2026 |
|---|
| Amy E. Miles | Director | 408 · < 1% | Grant or award, 19 May 2026 |
|---|
| Khosla Rachna | SVP, Business Development | — | Open-market sale, 13 Aug 2026 |
|---|
| Michael V. Drake | Director | — | Grant or award, 7 Aug 2026 |
|---|
| Busch Matthew C. | VP, Finance & CAO | — | Grant or award, 7 Aug 2026 |
|---|
| Miller Derek | SVP, Human Resources | — | Open-market sale, 6 Aug 2026 |
|---|
| Grygiel Nancy A. | SVP & CCO | — | Open-market sale, 6 Aug 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
AMGN in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.